Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance.

IF 3.2 2区医学 Q2 CLINICAL NEUROLOGY

Journal of Neuro-Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI:10.1007/s11060-024-04737-9

Myunghwan Lee, Philipp Karschnia, Yae Won Park, Kaeum Choi, Kyunghwa Han, Seo Hee Choi, Hong In Yoon, Na-Young Shin, Sung Soo Ahn, Joerg-Christian Tonn, Jong Hee Chang, Se Hoon Kim, Seung-Koo Lee

{"title":"Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance.","authors":"Myunghwan Lee, Philipp Karschnia, Yae Won Park, Kaeum Choi, Kyunghwa Han, Seo Hee Choi, Hong In Yoon, Na-Young Shin, Sung Soo Ahn, Joerg-Christian Tonn, Jong Hee Chang, Se Hoon Kim, Seung-Koo Lee","doi":"10.1007/s11060-024-04737-9","DOIUrl":null,"url":null,"abstract":"Purpose: Whether molecular glioblastomas (GBMs) identify with a similar dismal prognosis as a \"classical\" histological GBM is controversial. This study aimed to compare the clinical, molecular, imaging, surgical factors, and prognosis between molecular GBMs and histological GBMs.Methods: Retrospective chart and imaging review was performed in 983 IDH-wildtype GBM patients (52 molecular GBMs and 931 histological GBMs) from a single institution between 2005 and 2023. Propensity score-matched analysis was additionally performed to adjust for differences in baseline variables between molecular GBMs and histological GBMs.Results: Molecular GBM patients were substantially younger (58.1 vs. 62.4, P = 0.014) with higher rate of TERTp mutation (84.6% vs. 50.3%, P < 0.001) compared with histological GBM patients. Imaging showed higher incidence of gliomatosis cerebri pattern (32.7% vs. 9.2%, P < 0.001) in molecular GBM compared with histological GBM, which resulted in lesser extent of resection (P < 0.001) in these patients. The survival was significantly better in molecular GBM compared to histological GBM (median OS 30.2 vs. 18.4 months, P = 0.001). The superior outcome was confirmed in propensity score analyses by matching histological GBM to molecular GBM (P < 0.001).Conclusion: There are distinct clinical, molecular, and imaging differences between molecular GBMs and histological GBMs. Our results suggest that molecular GBMs have a more favorable prognosis than histological GBMs.","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-024-04737-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Whether molecular glioblastomas (GBMs) identify with a similar dismal prognosis as a "classical" histological GBM is controversial. This study aimed to compare the clinical, molecular, imaging, surgical factors, and prognosis between molecular GBMs and histological GBMs.

Methods: Retrospective chart and imaging review was performed in 983 IDH-wildtype GBM patients (52 molecular GBMs and 931 histological GBMs) from a single institution between 2005 and 2023. Propensity score-matched analysis was additionally performed to adjust for differences in baseline variables between molecular GBMs and histological GBMs.

Results: Molecular GBM patients were substantially younger (58.1 vs. 62.4, P = 0.014) with higher rate of TERTp mutation (84.6% vs. 50.3%, P < 0.001) compared with histological GBM patients. Imaging showed higher incidence of gliomatosis cerebri pattern (32.7% vs. 9.2%, P < 0.001) in molecular GBM compared with histological GBM, which resulted in lesser extent of resection (P < 0.001) in these patients. The survival was significantly better in molecular GBM compared to histological GBM (median OS 30.2 vs. 18.4 months, P = 0.001). The superior outcome was confirmed in propensity score analyses by matching histological GBM to molecular GBM (P < 0.001).

Conclusion: There are distinct clinical, molecular, and imaging differences between molecular GBMs and histological GBMs. Our results suggest that molecular GBMs have a more favorable prognosis than histological GBMs.

Abstract Image

查看原文本刊更多论文

分子和组织学胶质母细胞瘤的比较分析：对预后差异的见解。

目的：分子胶质母细胞瘤（GBM）的预后是否与 "经典 "组织学GBM相似尚存争议。本研究旨在比较分子型胶质母细胞瘤和组织学型胶质母细胞瘤的临床、分子、影像、手术因素和预后：方法：对2005年至2023年间来自一家机构的983例IDH野生型GBM患者（52例分子GBM和931例组织学GBM）进行了回顾性病历和影像学检查。此外还进行了倾向评分匹配分析，以调整分子GBM和组织学GBM之间基线变量的差异：结果：分子 GBM 患者更年轻（58.1 岁 vs. 62.4 岁，P = 0.014），TERTp 突变率更高（84.6% vs. 50.3%，P 结论：分子 GBM 与组织学 GBM 有不同的临床、分子和病理特征：分子 GBM 与组织学 GBM 在临床、分子和影像学方面存在明显差异。我们的研究结果表明，分子型 GBM 的预后比组织学型 GBM 更好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuro-Oncology 医学-临床神经学

CiteScore

6.60

自引率

7.70%

发文量

277

审稿时长

3.3 months

期刊介绍： The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.